Literature DB >> 12681531

Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats.

Giancarlo Colombo1, Salvatore Serra, Giuliana Brunetti, Giovanni Vacca, Mauro A M Carai, Gian Luigi Gessa.   

Abstract

Alcohol deprivation effect (ADE), i.e. the transient increase in alcohol intake that takes place in laboratory animals after a period of alcohol deprivation, has been proposed to model alcohol relapses in alcoholics. The present study investigated the effect of the GABA(B) receptor agonist, baclofen, on the development of ADE in selectively bred Sardinian alcohol-preferring (sP) rats. Acute administration of non-sedative doses of baclofen (0, 1, 1.7 and 3 mg/kg, i.p.) resulted in the complete suppression of the extra-amount of alcohol consumed during the first hour of re-access to alcohol after 7 days of deprivation. These results implicate the GABA(B) receptor in the neural substrate mediating ADE and suggest that baclofen may possess anti-relapse properties.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12681531     DOI: 10.1016/s0376-8716(02)00333-2

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  39 in total

Review 1.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

3.  Identification of a G-Protein-Independent Activator of GIRK Channels.

Authors:  Yulin Zhao; Peter Man-Un Ung; Gergely Zahoránszky-Kőhalmi; Alexey V Zakharov; Natalia J Martinez; Anton Simeonov; Ian W Glaaser; Ganesha Rai; Avner Schlessinger; Juan J Marugan; Paul A Slesinger
Journal:  Cell Rep       Date:  2020-06-16       Impact factor: 9.423

Review 4.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Factors mediating alcohol craving and relapse: stress, compulsivity, and genetics.

Authors:  Zachary A Rodd; Kristin K Anstrom; Darin J Knapp; Ildiko Racz; Andreas Zimmer; Salvatore Serra; Richard L Bell; Donald J Woodward; George R Breese; Giancarlo Colombo
Journal:  Alcohol Clin Exp Res       Date:  2005-07       Impact factor: 3.455

6.  Complete suppression of craving in alcohol-dependent individuals: is it possible?

Authors:  Falk Kiefer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 7.  Potential of GABAB Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder.

Authors:  Paola Maccioni; Giancarlo Colombo
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

8.  Multi-modal imaging reveals differential brain volumetric, biochemical, and white matter fiber responsivity to repeated intermittent ethanol vapor exposure in male and female rats.

Authors:  Natalie M Zahr; Aran M Lenart; Joshua A Karpf; Keriann M Casey; Kilian M Pohl; Edith V Sullivan; Adolf Pfefferbaum
Journal:  Neuropharmacology       Date:  2020-03-30       Impact factor: 5.250

9.  Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation.

Authors:  José Antonio López-Moreno; Gustavo González-Cuevas; Fernando Rodríguez de Fonseca; Miguel Navarro
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

Review 10.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.